Rifampicin, Isoniazid & Pyrazinamide Tablets (RHZ) – Manufacturer India

1. Product Introduction

Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter of Rifampicin, Isoniazid and Pyrazinamide tablets. RHZ combines three first-line antituberculosis medicines. The supplied range includes a single-tablet RIP fixed-dose combination and a combi pack containing three separately formulated tablets.

RHZ does not contain ethambutol and is not equivalent to the standard four-drug RHZE intensive-phase regimen. Use depends on treatment phase, susceptibility testing and current TB programme guidance. WHO-GMP certification, contract manufacturing capabilities and export registrations should be confirmed using current documentation.

2. Product Specifications

3. Manufacturing Technology

Formulation stability: Rifampicin and isoniazid can interact, and rifampicin stability and bioavailability require careful control. Validated granulation, excipient compatibility, moisture management and protective packaging are important development considerations.

Two distinct formats: A single-tablet RHZ FDC needs compatibility and dissolution evaluation for all three ingredients. A combi pack uses separately manufactured and packaged tablets. Claimed barrier granulation, micronized API, proprietary shielding or particular packaging machinery should be verified from manufacturing records before publication.

4. Quality Assurance

Release testing should follow each registered product specification and relevant pharmacopoeial requirements: identification, assay, dissolution, uniformity of dosage units, related substances, stability, packaging integrity and appropriate microbial quality controls.

Rifampicin degradation products and potential interaction products warrant particular attention. Fixed numerical limits and claims of bioequivalence must not be asserted without validated test methods and supporting data.

5. Mechanism and Therapeutic Uses

Rifampicin inhibits bacterial DNA-dependent RNA polymerase. Isoniazid inhibits mycolic acid synthesis. Pyrazinamide has activity against susceptible tuberculosis bacilli in specific host environments and is particularly valuable in selected intensive-phase regimens.

These drugs are used for susceptible Mycobacterium tuberculosis infection within an appropriate combination regimen. The standard drug-susceptible TB intensive-phase regimen commonly includes ethambutol in addition to rifampicin, isoniazid and pyrazinamide; this RHZ product alone does not provide all four drugs. Selection depends on national guidelines and drug-susceptibility results.

6. Export and Regulatory Support

B2B buyers should request current manufacturing licences, product approvals, batch certificates of analysis, stability and dissolution documentation, packaging specifications and applicable WHO-GMP evidence. CTD/ACTD dossiers, COPP, Free Sale Certificates, government tender eligibility, shipping terms and market-specific authorisations are subject to confirmation.

7. Frequently Asked Questions

Q: What is the difference between the two presentations?
A: RIP contains all three actives in one film-coated tablet (150/75/400 mg); the IP combi pack consists of three separate tablets (100 mg rifampicin, 50 mg isoniazid and 250 mg pyrazinamide).

Q: Does RHZ replace RHZE?
A: No. RHZ has no ethambutol. A TB specialist must determine the complete regimen.

Q: Why can urine appear orange-red?
A: Rifampicin commonly discolours urine, tears and other body fluids. Other symptoms such as jaundice need assessment.

Q: Can it be taken with food?
A: Follow the approved label and clinician advice; food can affect rifampicin absorption, but tolerability and formulation instructions matter.

8. Dosage and Administration

Prescription use only. Dose, number of tablets, administration schedule and duration are determined by weight band, age, organ function, drug susceptibility, formulation and the relevant national TB protocol. The separate-tablet combi pack must not be assumed dose-equivalent to a single RIP FDC tablet.

Follow the prescribed complete TB regimen. Never substitute RHZ for a four-drug regimen, skip an accompanying medicine, or discontinue treatment without medical supervision. Administration relative to meals should follow the specific approved product label.

9. Side Effects and Precautions

• Liver toxicity: Rifampicin, isoniazid and pyrazinamide can cause hepatotoxicity. New jaundice, dark urine with systemic symptoms, persistent vomiting or marked fatigue require urgent clinical assessment; monitoring is based on individual risk and guidelines.
• Peripheral neuropathy: Isoniazid can cause neuropathy; pyridoxine supplementation may be indicated according to clinical guidance.
• Hyperuricemia: Pyrazinamide can elevate uric acid and cause joint pain or precipitate gout.
• Drug interactions: Rifampicin is a strong enzyme inducer and can reduce exposure to numerous medicines, including hormonal contraceptives and some antiretrovirals.
• Body fluid colour: Orange-red discoloration from rifampicin is expected; soft contact lenses may stain.
• Resistance: Incomplete treatment and inappropriate regimens can lead to treatment failure and resistance.

10. Storage Instructions

Store in the original, tightly closed, approved packaging, protected from excess moisture, heat and direct light. Follow the temperature limit stated on the actual registered label; an unverified universal 25°C requirement should not be imposed.

Keep out of reach of children and do not use beyond the approved expiry date.